Novel reagents for transfection of eukaryotic cells
AssigneeMolecular Transfer, Inc.
InventorsJoel Jessee, Gulilat Gebeyehu
Life of this patent
Estimating the term…
Loading patent…
AssigneeMolecular Transfer, Inc.
InventorsJoel Jessee, Gulilat Gebeyehu
Estimating the term…
Compositions and methods for improved delivery of macromolecules into eukaryotic cells are provided. Fusogenic peptides from fusion proteins of non-enveloped viruses enhance the efficiency of transfection of eukaryotic cells mediated by transfection agents such as cationic lipids, polycationic polymers such as PEI and dendrimers. These fusogenic peptides are used as part of a transfection complex that efficiently delivers a macromolecule, for example, a nucleic acid, into a eukaryotic cell. Novel cationic lipids and compositions of cationic lipids also are provided that may be used for the introduction of macromolecules such as nucleic acids, proteins and peptides into a variety of cells and tissues. The lipids can be used alone, in combination with other lipids and/or in combination with fusogenic peptides to prepare transfection complexes.
A complex comprising a transfection agent and a fusion agent, wherein said fusion agent comprises a fusion promoting amino acid sequence derived from a fusion protein of a non-enveloped virus.
(canceled)
10-15. (canceled)
17-20. (canceled)
23-28. (canceled)
30-32. (canceled)
A method for introducing a nucleic acid, protein, or peptide into a cell, comprising contacting the cell with a complex comprising the nucleic acid, protein, or peptide a transfection agent, and a fusion agent, wherein said fusion agent comprises a fusion promoting amino acid sequence derived from a fusion protein of a non-enveloped virus, thereby introducing the nucleic acid, protein, or peptide into the cell.
34-45. (canceled)
A kit comprising a nucleic acid binding moiety and a peptide or protein or a modified peptide or modified protein derived from a fusion promoting amino acid sequence of a Reovirus.
48-63. (canceled)
(canceled)
67-69. (canceled)
(canceled)
(canceled)
85-86. (canceled)
(canceled)
92-100. (canceled)
107-108. (canceled)
110-111. (canceled)
115-154. (canceled)
Dependencies are inferred from the claim text.